trending Market Intelligence /marketintelligence/en/news-insights/trending/w3UAjevc0k7qDDyHr6YOmQ2 content esgSubNav
In This List

Brazilian regulator approves Arena, Eisai weight management drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Brazilian regulator approves Arena, Eisai weight management drug

Arena Pharmaceuticals Inc. and Eisai Inc. said the latter's Eisai Laboratórios Ltda. received regulatory approval from the Brazilian Health Surveillance Agency, ANVISA, for chronic weight management drug Belviq.

The drug will be available following review by Brazil's Medicines Market Regulation Board, which will trigger a $1 million milestone payment to Arena.

Belviq is approved in Brazil for use by obese and overweight patients with at least one weight-related comorbid condition, such as high blood pressure, high cholesterol or cardiovascular disease.

Belviq is approved for weight management in the U.S. and South Korea. The drug is also available in Mexico under the brand name Venespri.

Eisai Inc. is the U.S. unit of Japan-based Eisai Co. Ltd.